Summary:
The purpose of this study is to evaluate the efficacy and the safety of two doses of CHF6001 (Tanimilast) as add-on to maintenance triple therapy in the target patient population.
Qualified Participants Must:
• Adults aged 40 years and older, with COPD and with chronic bronchitis
•
Current smokers or ex-smokers (history of 10 pack years or higher)
•
Post-bronchodilator FEV1 less than 50% of the patient predicted normal value and FEV1/FVC ratio less than 0.7
•
At least, one moderate or severe COPD exacerbation in the previous year
•
CAT score greater than 10
•
Subjects on regular maintenance triple therapy for at least 12 months
Qualified Participants May Receive:
May receive reimbursement for time and travel for study participation, if you qualify.